Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer

详细信息    查看全文

• 作者：Xiaoti Lin (1) (2) (3)
  Minqing Wu (2) (4)
  Peng Liu (1) (2)
  Fengqin Wei (5)
  Laisheng Li (6)
  Hailin Tang (1) (2)
  Xinhua Xie (1) (2)
  Xiaoping Liu (1) (2)
  Lu Yang (1) (2)
  Xiaoming Xie (1) (2)
  
• 关键词：TARBP2 ; Breast cancer ; Tumor promotor ; Prognostic factor
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：31
• 期：4
• 全文大小：10,539 KB
• 参考文献：1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-1.
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-0.
  3. Autier P, Hery C, Haukka J, et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27(35):5919-3.
  4. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-2.
  5. Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-6.
  6. Mahoney MC, Newell MS. Breast intervention: how i do it. Radiology. 2013;268(1):12-4.
  7. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics 2011. CA Cancer J Clin. 2011;61(6):409-8.
  8. Lee E, McKean-Cowdin R, Ma HY, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29(33):4373-0.
  9. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852-.
  10. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-4.
  11. Metzger O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879-7.
  12. Devi BC, Tang TS, Corbex M. Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4?years: a pilot study of clinical downstaging in Sarawak. Malays Ann Oncol. 2007;18(7):1172-.
  13. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, et al. Male breast cancer. Cancer Treat Rev. 2010;36(6):451-.
  14. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27):4515-1.
  15. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-.
  16. Benkirane M, Neuveut C, Chun RF, et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 1997;16(3):611-4.
  17. Gatignol A, Buckler-White A, Berkhout B, et al. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science. 1991;251(5001):1597-00.
  18. Gatignol A, Duarte M, Daviet L, et al. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 1996;5(4-):217-8.
  19. Bai S, Nunez AL, Wei S, et al. Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. Am J Clin Pathol. 2013;139(6):765-0.
  20. De Vito C, Riggi N, Cornaz S, et al. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012;21(6):807-1.
  21. Melo SA, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41(3):365-0.
  22. Caramuta S, Lee L, Ozata DM, et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(4):551-4.
  23. Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA. 2011;108(11):4394-.
  24. Fu X, Xue C, Huang Y, et al. The activity and expression of microRNAs in prostate cancers. Mol BioSyst. 2010;6(12):2561-2.
  25. Sand M, Skrygan M, Georgas D, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012;350(1):119-6.
  26. Sand M, Skrygan M, Georgas D, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2012;51(11):916-2.
  27. Wu M, Wei W, Xiao X, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012;29(5):3240-.
  28. Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641-.
  29. Stephan EA, Chung TH, Grant CS, et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 2008;7(2):425-1.
  30. Bannwarth S, Talakoub L, Letourneur F, et al. Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line. J Biol Chem. 2001;276(52):48803-3.
  31. Park H, Davies MV, Langland JO, et al. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci USA. 1994;91(11):4713-.
  32. Francois C, Duverlie G, Rebouillat D, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 2000;74(12):5587-6.
  33. Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci. 2012;69(21):3587-9.
  34. Yu Z, Pestell RG. Small non-coding RNAs govern mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2012;17(1):59-4.
  35. Si ML, Zhu S, Wu H, Lu Z, et al. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799-03.
  36. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28(4):341-.
  37. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-.
  38. Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67(22):11001-1.
  39. Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010;141(7):1195-07.
  40. Ibarra I, Erlich Y, Muthuswamy SK, et al. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev. 2007;21(24):3238-3.
  41. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-.
  42. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109-3.
  43. Lehmann U, Hasemeier B, Christgen M, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008;214(1):17-4.
  44. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-0.
  45. Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194-04.
  46. Li LS, Xie XH, Luo JM, et al. Targeted expression of miR-34a using the T-VISA System suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20(12):2326-4.
  47. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592-03.
  48. Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722-0.
  
• 作者单位：Xiaoti Lin (1) (2) (3)
  Minqing Wu (2) (4)
  Peng Liu (1) (2)
  Fengqin Wei (5)
  Laisheng Li (6)
  Hailin Tang (1) (2)
  Xinhua Xie (1) (2)
  Xiaoping Liu (1) (2)
  Lu Yang (1) (2)
  Xiaoming Xie (1) (2)
  
  1. Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
  2. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
  3. Department of Surgery, Fujian Provincial Tumor Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, 350014, People’s Republic of China
  4. Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
  5. Department of Emergency, Fujian Provincial 2nd People’s Hospital, Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350000, People’s Republic of China
  6. Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, People’s Republic of China
  
• ISSN：1559-131X

文摘

Expression of trans-activation-responsive-RNA-binding protein 2 (TARBP2) varied from normal cell lines to various cancer cell lines. The discussion of TARBP2 serve as tumor suppressor or tumor promotor goes on. However, its expression in breast cancer remains unknown. The aim of present study was to assess the expression of cytoplasm TARBP2 as potential prognostic marker in breast cancer. We further investigated cytoplasm TARBP2 could be a novel target in treatment for late-stage breast cancer and triple-negative breast cancer (TNBC). A total of patients with breast cancer were involved in our cohort. Immunohistochemical staining for TARBP2 on tissue microarray and western blot were used. Immunohistochemistry showed that cytoplasm TARBP2 was frequently up-regulated in breast carcinoma. This finding was in line with the result of western blot analysis. Further investigation showed that cytoplasm TARBP2 expression in non-TNBC was higher than that of their adjacent normal breast tissues (NBT), and TNBC was the highest of the three groups. The positive expression of cytoplasm TARBP2 in stage III breast cancer, stage I–II breast cancer, and NBT decreased gradually. In addition, univariate and multivariate survival analysis revealed cytoplasm TARBP2 was an independent prognostic factor for breast cancer. Breast cancer patients with cytoplasm TARBP2 expression had poorer disease-free survival and overall survival, and similar results were obtained in TNBC group and stage III breast cancer group. Our results provide convincing evidence for the first time that the expression of cytoplasm TARBP2 is up-regulated in breast cancer. Breast cancer patients with TARBP2 cytoplasm expression have unfavorable prognosis. Patients of TNBC and late-stage breast cancer with higher cytoplasm TARBP2 expression have an unfavorable prognosis.